Medication time response

Medication time response is the time period that passes between when the medication is administered to the patient and the pharmaceutical response. There are three types of medication time responses. These are ... 

Swanson, J., Kinsbourne, M., Roberts, W, and Zucker, K. (1978) Time-response analysis of the effect of stimulant medication on... 

Onset Time Response The minimum concentration of the medication to cause the initial pharmaceutical response... 

Peak Time Response The period when the medication has its highest blood or plasma concentration... 

The primary objective of an industry-based medical information department is to provide accurate, well-balanced, and timely responses to inquiries regarding a company s products. However, the department can be involved in every aspect of the life cycle of a pharmaceutical product. The level of that involvement depends on the size and organization of the company, as well as the initiative and creativity of the medical information staff. 

Mobile health (mHealth) is an emerging concept which refers to the combinational use of mobile computing, communication technologies, and medical sensors for healthcare [1]. In addition to the passive provision of health-related information via mobile platforms, its scope also extends to more active applications such as disease management, medical prognosis, diagnosis, and even treatment. A typical mHealth system is characterized by its features of mobility, wireless connectivity, location independence, and timely response— which together provide seamless and personalized healthcare. 

The phrase in near proximity to the workplace does not directly relate to any specific distance. In medical emergencies, response time is a more relevant measure. Sufficient response time for medical assistance is to be based on an assessment of workplace hazards and the possible outcomes that could occur. 

To the best of the Publisher s knowledge the information contained in this book is accurate however, the Publisher assumes no responsibility nor liability for errors or any consequences arising from the use of the information contained herein. Final determination of the suitability of any information, procedure, or product for use contemplated by any user, and the manner of that use, is the sole responsibility of the user. The book is intended for informational purposes only. Due caution should be exercised in the use and handling of those raw materials that are potentially hazardous. Expert advice should be obtained at all times when manufacturing implementation is being considered. In the case of personal use of any of the products included, the manufacturer s medical instructions should be followed. Mention of trade names does not indicate endorsement by the Author nor the Publisher. 

An ongoing assessment is one that is made at the time of each patient contact and may include the collection of objective data, subjective data, or both. The scope of an ongoing assessment depends on many factors, such as the patient s diagnosis, the severity of illness, the response to treatment, and the prescribed medical or surgical treatment. 

Promoting an Optimal Response to Therapy Treatment with a leprostatic drug may require many years. These patients are faced with long-term medical and drug therapy and possibly severe disfigurement. The nurse must spend time with these patients, allowing them to verbalize their anxieties, problems, and fears. 

The most common reason for lack of rt-PA use in otherwise eligible patients remains, however, delay in presentation to the hospital. The California Acute Stroke Pilot Registry (CASPR) investigators examined the effect of various hypothetical interventions on the rate of rt-PA use. Their data suggested that if all patients with a known time of onset presented to medical attention immediately, the expected overall rate of thrombolytic treatment within 3 hours would have increased from 4.3% to 28.6%. By comparison, the expected rate of treatment that would result from instantaneous prehospital response was 5.5%, from perfect hospital care was 11.5%, and from extension of time window to 6 hours was 8.3%. 

Natural products have been noted for their potential health benefits from time immemorial and are the basis of Ayurveda, an ancient Indian medical practice (Bushkin and Bushkin, 2002). However, the potential benefits of several natural products reside in one or two active ingredients. For example green tea stands for polyphenols, soy for soy estrogens, broccoli for isothiocyanates and grape seed for polyphenols. The beauty of rice bran is that there are more than 100 antioxidants, several categories of bioactive phytonutrients, such as IP6, polyphenols, phytosterols, tocotrienols, y-oryzanol, B vitamins, minerals and trace minerals in addition to fat, protein, fiber, polysaccharides and other nutrients. These phytonutrients and antioxidants of rice bran are believed to act at the cellular level, and their synergestic function is responsible for the positive health benefits. 

Assess the patient s response to initiation of DMARD therapy after allowing adequate time for the medication to achieve its therapeutic effect. 

---